Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer

NCT00493857 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Cohort 2 not going forward. Manadate changes in Company

Conditions

Colorectal Cancer

Interventions

DRUG: Nimotuzumab Humanized Monoclonal Antibody
DRUG: Nimotuzumab

Sponsor

YM BioSciences